Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bacopa Monnieri vs Huperzine A: Bacopa Monnieri has the stronger overall evidence (6 vs 6/10); they're alternatives for improve memory & learning — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Bacopa Monnieri wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
1 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (3)
Outcomes where both Bacopa Monnieri and Huperzine A have evidence — compare verdict strength side-by-side.
300-450mg daily (standardized to 50% bacosides)
With fatty meal for absorption
Bacognize® or Synapsa® standardized extract
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
and 1 more not shown
8-12 weeks
8-12 weeks
First 2 weeks
First week
2-4 weeks
30-60 minutes
2-4 weeks
During use
Efficiency of Different Supplements in Alleviating Symptoms of ADHD with or Without the Use of Stimulants: A Systematic Review
Nutrients (2025) · Systematic review
The evidence revealed the potential use of supplements as complementary ADHD treatments under clinical guidance.
Effectiveness of Bacopa Monnieri (Brahmi) in the management of schizophrenia: a systematic review
Nutritional neuroscience (2025) · Systematic review
Schizophrenia is a psychotic disorder affecting approximately 0.32% of the global population.
Bacopa monnieri: Preclinical and Clinical Evidence of Neuroactive Effects, Safety of Use and the Search for Improved Bioavailability
Nutrients (2025) · Review
Animal studies have shown promising results in reducing symptoms and protecting against neurodegeneration.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=70
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
The 300 mg point rests on four 12-week placebo-controlled trials of standardised extracts at 300 mg a day. Three found better verbal learning or delayed recall than placebo (PMID 11498727, 20590480 with 98 older adults, 18611150 with 54 adults over 65). The largest, 101 adults with memory complaints (PMID 41091332), found no difference in verbal learning, attention or working memory. The 160 mg point is one 2-month trial in 62 people with mild cognitive impairment (PMID 38538390): attention improved, and the overall cognitive score differed from placebo only at the final visit. No trial compared doses within one study, and none gave more than 300 mg a day for weeks, so no optimal dose or safety ceiling can be read from them. Two trials reported more gastrointestinal complaints on bacopa.
Doses are per day. At 200 mcg (0.1 mg twice daily), a double-blind trial in 78 people with mild to moderate vascular dementia improved MMSE, CDR and daily living scores over 12 weeks (PMID 21833673). At 400 mcg (200 mcg twice daily), the primary analysis of a phase II trial in 210 people with Alzheimer's disease found no effect on ADAS-Cog at 16 weeks, so the curve stays flat rather than rising (PMID 21502597). At 800 mcg (400 mcg twice daily), the same trial found a 2.27-point ADAS-Cog gain at 11 weeks that was no longer significant at 16 weeks. A meta-analysis of four trials using 300 to 500 mcg a day found MMSE and daily living gains (PMID 19221692). The trials are in different populations and only one compared doses, so no minimum, optimal or safe ceiling is set.
AI-estimated from published studies. Interpret as directional guidance.
Bacopa Monnieri has a higher evidence score (6/10 vs 6/10) and wins in 2 of 3 categories.
For improve memory & learning, Bacopa Monnieri has a higher relevance score (95 vs 72).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.